Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the closing of its upsized initial public offering of 19,262,500 shares of its common stock at a public offering price of $18.00 per share, including 2,512,500 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares of common stock were sold by Hemab.

Hemab’s common stock began trading on the Nasdaq Global Select Market on Friday, May 1, 2026, under the ticker symbol “COAG.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Hemab, were approximately $346.7 million. The offering closed on May 4, 2026.

WilmerHale advised Hemab in the offering.

The WilmerHale team was led by Cynthia Mazareas and Scott Lunin and included Katharine Patterson, Hilary Baker-Jennings, Michaela Rosen, Joseph Odegaard, and Kelly Pagniello.